Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

Halofuginone improves muscle-cell survival in muscular dystrophies.

Bodanovsky A, Guttman N, Barzilai-Tutsch H, Genin O, Levy O, Pines M, Halevy O.

Biochim Biophys Acta. 2014 Jul;1843(7):1339-47. doi: 10.1016/j.bbamcr.2014.03.025. Epub 2014 Apr 2.

2.

Halofuginone promotes satellite cell activation and survival in muscular dystrophies.

Barzilai-Tutsch H, Bodanovsky A, Maimon H, Pines M, Halevy O.

Biochim Biophys Acta. 2016 Jan;1862(1):1-11. doi: 10.1016/j.bbadis.2015.10.007. Epub 2015 Oct 8.

3.

Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion.

Roffe S, Hagai Y, Pines M, Halevy O.

Exp Cell Res. 2010 Apr 1;316(6):1061-9. doi: 10.1016/j.yexcr.2010.01.003. Epub 2010 Jan 11.

PMID:
20060825
4.

Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone.

Turgeman T, Hagai Y, Huebner K, Jassal DS, Anderson JE, Genin O, Nagler A, Halevy O, Pines M.

Neuromuscul Disord. 2008 Nov;18(11):857-68. doi: 10.1016/j.nmd.2008.06.386. Epub 2008 Jul 30.

PMID:
18672370
5.

Transforming growth factor type-β inhibits Mas receptor expression in fibroblasts but not in myoblasts or differentiated myotubes; Relevance to fibrosis associated to muscular dystrophies.

Cofre C, Acuña MJ, Contreras O, Morales MG, Riquelme C, Cabello-Verrugio C, Brandan E.

Biofactors. 2015 Mar-Apr;41(2):111-20. doi: 10.1002/biof.1208. Epub 2015 Mar 23. Erratum in: Biofactors. 2015 May 6;41(3):209.

PMID:
25809912
6.

Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone.

Huebner KD, Jassal DS, Halevy O, Pines M, Anderson JE.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1550-61. doi: 10.1152/ajpheart.01253.2007. Epub 2008 Feb 8.

7.

Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone.

Halevy O, Genin O, Barzilai-Tutsch H, Pima Y, Levi O, Moshe I, Pines M.

Histol Histopathol. 2013 Feb;28(2):211-26. doi: 10.14670/HH-28.211.

PMID:
23275304
8.

Focusing on fibrosis: halofuginone-induced functional improvement in the mdx mouse model of Duchenne muscular dystrophy.

McLoon LK.

Am J Physiol Heart Circ Physiol. 2008 Apr;294(4):H1505-7. doi: 10.1152/ajpheart.00176.2008. Epub 2008 Feb 29. No abstract available.

9.

Halofuginone and muscular dystrophy.

Pines M, Halevy O.

Histol Histopathol. 2011 Jan;26(1):135-46. doi: 10.14670/HH-26.135. Review.

PMID:
21117034
10.
11.

Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy.

Percival JM, Whitehead NP, Adams ME, Adamo CM, Beavo JA, Froehner SC.

J Pathol. 2012 Sep;228(1):77-87. doi: 10.1002/path.4054. Epub 2012 Jul 18.

12.

The involvement of collagen triple helix repeat containing 1 in muscular dystrophies.

Spector I, Zilberstein Y, Lavy A, Genin O, Barzilai-Tutsch H, Bodanovsky A, Halevy O, Pines M.

Am J Pathol. 2013 Mar;182(3):905-16. doi: 10.1016/j.ajpath.2012.11.004. Epub 2012 Dec 27.

PMID:
23274062
13.

Inhibition of transforming growth factor beta signaling by halofuginone as a modality for pancreas fibrosis prevention.

Zion O, Genin O, Kawada N, Yoshizato K, Roffe S, Nagler A, Iovanna JL, Halevy O, Pines M.

Pancreas. 2009 May;38(4):427-35. doi: 10.1097/MPA.0b013e3181967670.

PMID:
19188864
14.

Matrix metalloproteinase-9 inhibition improves proliferation and engraftment of myogenic cells in dystrophic muscle of mdx mice.

Hindi SM, Shin J, Ogura Y, Li H, Kumar A.

PLoS One. 2013 Aug 15;8(8):e72121. doi: 10.1371/journal.pone.0072121. eCollection 2013.

15.

Hydroxy group requirement for halofuginone-dependent inhibition of muscle fibrosis and improvement of histopathology in the mdx mouse model for Duchenne muscular dystrophy.

Wellner G, Mordechay S, Evans P, Genin O, Pines M, Halevy O.

Histol Histopathol. 2019 Jan 10:18083. doi: 10.14670/HH-18-083. [Epub ahead of print]

PMID:
30628720
16.

Decrease of myofiber branching via muscle-specific expression of the olfactory receptor mOR23 in dystrophic muscle leads to protection against mechanical stress.

Pichavant C, Burkholder TJ, Pavlath GK.

Skelet Muscle. 2016 Jan 21;6:2. doi: 10.1186/s13395-016-0077-7. eCollection 2016.

17.

Elevated Expression of Moesin in Muscular Dystrophies.

Pines M, Levi O, Genin O, Lavy A, Angelini C, Allamand V, Halevy O.

Am J Pathol. 2017 Mar;187(3):654-664. doi: 10.1016/j.ajpath.2016.11.013. Epub 2017 Jan 9.

PMID:
28082118
18.

Fibrosis inhibition and muscle histopathology improvement in laminin-alpha2-deficient mice.

Nevo Y, Halevy O, Genin O, Moshe I, Turgeman T, Harel M, Biton E, Reif S, Pines M.

Muscle Nerve. 2010 Aug;42(2):218-29. doi: 10.1002/mus.21706.

PMID:
20589893
19.

Induction of CCAAT/Enhancer-Binding Protein β Expression With the Phosphodiesterase Inhibitor Isobutylmethylxanthine Improves Myoblast Engraftment Into Dystrophic Muscle.

Lala-Tabbert N, Fu D, Wiper-Bergeron N.

Stem Cells Transl Med. 2016 Apr;5(4):500-10. doi: 10.5966/sctm.2015-0169. Epub 2016 Mar 3.

20.

Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction.

Alexakis C, Partridge T, Bou-Gharios G.

Am J Physiol Cell Physiol. 2007 Aug;293(2):C661-9. Epub 2007 May 2.

Supplemental Content

Support Center